BiotechDispatch - Biotech

Latest News

Research shows gut microbiome could delay onset of type 1 diabetes
April 3, 2025
Latest News

Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial
April 3, 2025
Latest News

Biome secures news debt facility to support growth
April 3, 2025

Latest News Algorae announces the appointment of chief commercial officer April 3, 2025
Algorae Pharmaceuticals (ASX:1AI) has announced the appointment of experienced pharmaceutical executive Vishal Shah as its chief commercial officer.
Latest News Percheron updates shareholders after disappointing clinical trial result April 3, 2025
Percheron Therapeutics (ASX:PER) has updated shareholders on its actions following the disappointing result in the Phase 2b trial of its avicursen in non-ambulant boys with Duchenne muscular dystrophy.
Latest News GSK brings Melbourne discovered treatment 'home' to Australian patients April 1, 2025
The Melbourne scientists who developed OMJJARA, Professor Andrew Wilks and Dr Chris Burns, said, “Today’s PBS milestone is our ‘full circle’ moment."
Latest News Opthea announces decision to discontinue wet-AMD clinical trials April 1, 2025
Opthea (ASX:OPT) has announced it will discontinue clinical trials involving its sozinibercept in combination with other therapies for treating wet age-related macular degeneration.
Latest News Cyclopharm announces significant US milestone for Technegas sales April 1, 2025
Cyclopharm (ASX:CYC) has announced that the US commercial sales of Technegas have now exceeded $US1 million following its launch last year.
Latest News BioNSW launches BioInvest Catalyst events to support life sciences investment in NSW April 1, 2025
BioNSW has launched its inaugural BioInvest Catalyst event. The organisation said the three-part event series aims to foster deeper engagement between investors and life science entrepreneurs.
Latest News Artrya secures contract with Lumus Imaging for use of Salix Coronary Anatomy April 1, 2025
Medical technology company Artrya (ASXAYA) has announced a commercial contract with Lumus Imaging for the use of the Salix Coronary Anatomy platform.
AusBiotech AusBiotech says life sciences is the ‘sleeping giant’ of Australian economy March 27, 2025
AusBiotech says that while the 2025-26 Budget did not include significant new commitments for Australia’s life sciences sector, it remains steadfast in its advocacy to unlock this critical sector's full potential.
Latest News Mesoblast says its FDA-approved mesenchymal stromal cell therapy available for sale in the US March 27, 2025
Mesoblast (ASX:MSB) has announced that its FDA-approved Ryoncil (remestemcel-L) mesenchymal stromal cell therapy is now available for purchase in the US.
Latest News Neuren initiates development of NNZ-2591 to treat HIE in newborns March 27, 2025
Neuren Pharmaceuticals (ASX:NEU) has initiated the development of NNZ-2591 to treat hypoxic-ischemic encephalopathy.
Latest News Clinuvel announces positive preliminary results for PRÉNUMBRA Instant in stroke patients March 27, 2025
Clinuvel (ASX:CUV) has released preliminary results from its second clinical study investigating its drug afamelanotide as a treatment for arterial ischaemic stroke.
Latest News Amplia Therapeutics reports updated data from pancreatic cancer trial March 27, 2025
Amplia Therapeutics (ASX:ATX) has reported updated data from its ongoing Phase 2a ACCENT clinical trial investigating its FAK inhibitor narmafotinib in combination with standard-of-care chemotherapy in treating advanced pancreatic cancer.
Latest News Nanotechnology could improve odds in treating aggressive breast cancers March 25, 2025
University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.
Latest News Opthea now managing the fallout of clinical trial result March 25, 2025
Opthea (ASX:OPT) has reported negative outcomes from its pivotal Phase 3 clinical trial involving the combination of its sozinibercept with Bayer's EYLEA (aflibercept) for treating wet age-related macular degeneration.
Latest News First patient dosed in Immutep’s TACTI-004 Phase 3 non-small cell lung cancer trial March 25, 2025
Immutep (ASX:IMM) has announced that the first patient has been successfully dosed in its pivotal TACTI-004 Phase 3 trial.
Latest News Noxopharm expands collaboration with Hudson Institute March 25, 2025
Noxopharm (ASX:NOX) has announced an expanded work program for 2025 with its strategic partner, Melbourne’s Hudson Institute of Medical Research.
Latest News Chimeric announces US patent allowed for CHM CDH17 technology March 25, 2025
Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the US Patent and Trademark Office has allowed the issuance of a patent application covering the company's CHM CDH17 chimeric antigen receptor technology.

Most Read

New Stories